Filed under: Newsletters, Teva Pharm Indus ADR (TEVA), Stocks to Buy
“OncoGenex Pharmaceuticals (OGXI) recently released their fourth quarter and year end 2010 financial results; during the conference call they discussed updates in their development programs and provided an outlook for 2011,” notes biotech specialist John McCamant.
The editor of the Medical Technology Stock Letter continues, “The company reported a Q4 2010 net loss of $2.8 million or ($0.26) per share compared to Q4 2009 net profit of $3.9 million or $0.70 per share.
“OGXI finished the year in a solid position financially with $85.6 million in cash. The company expects to end 2011 with $50-$54 million on the balance sheet and use $31-$35 million in operating cash. They appear to have enough cash to fund operations into 2014.
Continue reading OncoGenex (OGXI): Biotech Targets Cancer Treatments
OncoGenex (OGXI): Biotech Targets Cancer Treatments originally appeared on BloggingStocks on Wed, 06 Apr 2011 10:00:00 EST. Please see our terms for use of feeds.
Permalink | Email this | Comments
“Most of us have probably checked out out the annual lists of companies that are good to work for, but Parnassus Workplace (
This post is part of 
“Benjamin Graham has been recognized for decades as the father of value investing; Warren Buffett was a student of Ben Graham at Columbia University and later worked for Mr. Graham for several years,” notes 
